0000875320VERTEX PHARMACEUTICALS INC / MAEX-FILING FEESfalseN/Axbrli:sharesiso4217:USDxbrli:sharesiso4217:USDxbrli:pure00008753202026-05-132026-05-13000087532012026-05-132026-05-13

Exhibit 107

Calculation of Filing Fee Tables

Form S-8

(Form Type)

Vertex Pharmaceuticals Incorporated

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type						Security Class Title			Fee Calculation Rule			Amount Registered(1)			Proposed Maximum Offering Price Per Share(2)			Maximum Aggregate Offering Price(2)			Fee Rate			Amount of Registration Fee(2)
Equity						Common stock, $0.01 par value per share			457(c) and 457(h)			6,400,000			$426.53			$2,729,792,000			$0.0001381			$376,984.28
Total Offering Amounts																		$2,729,792,000						$376,984.28
Total Fee Offsets																								$0.00
Net Fee Due																								$376,984.28
(1)			Consists of 6,400,000 shares of common stock, par value $0.01 per share, that may be issued under the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the “2026 Plan”) that became effective May 13, 2026 (the “Effective Date”). The maximum number of shares that may be issued under the 2026 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2026 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares that may be subject to grant or otherwise issuable after the operation of any such anti-dilution provisions, stock splits, or other similar transactions.
(2)			Pursuant to Rules 457(c) and 457(h) under the Securities Act, the registration fee was computed on the basis of the average of the high and low prices of the registrant’s common stock on the Nasdaq Global Select Market on May 8, 2026.